December 02, 2019 — Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that it has submitted a New Drug Application (NDA), under section 505(b)(2) of the…Original Article
Alkindi New Drug Application Submitted to US FDA
